BACKGROUND: It is not sufficient to predict 'high allergic risk newborns' on the basis of increased IgE concentrations of cord blood alone, because a raised cord blood IgE concentration is specific but not sensitive in the prediction of the development of allergic disorders. Warner et al. have reported that interferon gamma (IFN-gamma) production by allergen-triggered cord blood cells is a predictor of atopic eczema, based on the 1-year follow-up study. OBJECTIVE: We examined whether IFN-gamma production by antigen-stimulated cord blood mononuclear cells (CBMCs) is a risk factor of allergic disorders, based on the 6-year follow-up study. METHODS: The relationships among cord blood IgE concentrations, IFN-gamma and interleukin-2 (IL-2) productions by antigen-stimulated CBMCs, and the development of allergic disorders in 21 infants for 6 years were investigated. RESULTS: Atopic dermatitis, atopic dermatitis and allergic rhinitis, or atopic dermatitis and bronchial asthma developed in seven of 21 subjects. The maximal IFN-gamma concentration in culture supernatants of ovalbumin (OA) or bovine serum albumin (BSA) stimulated CBMCs in infants who developed allergic disorders was significantly lower (P < 0.01) than that in infants who did not develop any allergic disorders. In contrast, the maximal IL-2 concentration in culture supernatants of OA- or BSA-stimulated CBMCs in infants who developed allergic disorders was not lower than in infants who did not develop any allergic disorders. Moreover, the IFN-gamma concentrations were negatively correlated with cord blood IgE concentrations. CONCLUSION: Reduced IFN-gamma production by antigen-stimulated CBMCs is a risk factor of allergic disorders.
BACKGROUND: It is not sufficient to predict 'high allergic risk newborns' on the basis of increased IgE concentrations of cord blood alone, because a raised cord blood IgE concentration is specific but not sensitive in the prediction of the development of allergic disorders. Warner et al. have reported that interferon gamma (IFN-gamma) production by allergen-triggered cord blood cells is a predictor of atopic eczema, based on the 1-year follow-up study. OBJECTIVE: We examined whether IFN-gamma production by antigen-stimulated cord blood mononuclear cells (CBMCs) is a risk factor of allergic disorders, based on the 6-year follow-up study. METHODS: The relationships among cord blood IgE concentrations, IFN-gamma and interleukin-2 (IL-2) productions by antigen-stimulated CBMCs, and the development of allergic disorders in 21 infants for 6 years were investigated. RESULTS:Atopic dermatitis, atopic dermatitis and allergic rhinitis, or atopic dermatitis and bronchial asthma developed in seven of 21 subjects. The maximal IFN-gamma concentration in culture supernatants of ovalbumin (OA) or bovine serum albumin (BSA) stimulated CBMCs in infants who developed allergic disorders was significantly lower (P < 0.01) than that in infants who did not develop any allergic disorders. In contrast, the maximal IL-2 concentration in culture supernatants of OA- or BSA-stimulated CBMCs in infants who developed allergic disorders was not lower than in infants who did not develop any allergic disorders. Moreover, the IFN-gamma concentrations were negatively correlated with cord blood IgE concentrations. CONCLUSION: Reduced IFN-gamma production by antigen-stimulated CBMCs is a risk factor of allergic disorders.
Authors: Jennifer M Babik; Deborah Cohan; Alexander Monto; Dennis J Hartigan-O'Connor; Joseph M McCune Journal: J Infect Dis Date: 2011-01-15 Impact factor: 5.226
Authors: A-K Larsson; C Nilsson; A Höglind; E Sverremark-Ekström; G Lilja; M Troye-Blomberg Journal: Clin Exp Immunol Date: 2006-06 Impact factor: 4.330
Authors: Sabine Hoffjan; Dan Nicolae; Irina Ostrovnaya; Kathy Roberg; Michael Evans; Daniel B Mirel; Lori Steiner; Karen Walker; Peter Shult; Ronald E Gangnon; James E Gern; Fernando D Martinez; Robert F Lemanske; Carole Ober Journal: Am J Hum Genet Date: 2005-02-22 Impact factor: 11.025
Authors: B Schaub; K G Tantisira; F K Gibbons; H He; A A Litonjua; M W Gillman; S Weiss; D L Perkins; D R Gold; P W Finn Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317